This may explain why DCHT is considered as a treatment of obesity and hyperlipidemia (Umeda et al., 1989; Han et al., 2020), since PPARα plays a central role in the onset and progression of these diseases (Xu et al., 2018). Here, STK39 is linked to hyperlipidemia.